Gradient Investments’s Neurocrine Biosciences NBIX Stock Holding History

Gradient Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-34	Closed	-$3K	–	1286
2021 Q4	$3K	Buy	+34	New	+$3.13K	﹤0.01%	1021

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Gradient Investments's NBIX Position: Q1 2022 in Review

Gradient Investments sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 34 shares — an estimated $3K sold.

Gradient Investments first reported a position in NBIX in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

Gradient Investments reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
Gradient Investments sold 34 Neurocrine Biosciences shares in Q1 2022, an estimated $3K.
Gradient Investments first reported a position in Neurocrine Biosciences in Q4 2021 and held it in 1 quarter.
Gradient Investments's Neurocrine Biosciences position peaked at $3K in Q4 2021.
426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Gradient Investments's 13F filing for Q1 2022, filed 26 May 2022.